Aug 6, 2026 · 41 min
Eight stocks face defining tests this reporting season
Stock Take: Eight Results That Matter
The episode identifies the operational milestones, competitive threats and valuation questions that could reshape eight investment cases.
- 1Lovisa’s international growth and inventory discipline face another test as expansion raises reporting risk.
- 2Healthcare names Cochlear, CSL, ResMed and Sonic Healthcare hinge on recovery, competition, demand and leadership signals.
- 3Mineral Resources, REA Group and FDC Consolidated expose contrasting risks around cash flow, AI disruption and capital allocation.
Don't miss
The discussion weighs whether Mineral Resources’ improving cash flow can overcome commodity volatility and uncertainty around future capital allocation.
The brief
John Addis, Gaurav Sodhi and Graham Witcomb preview eight companies whose upcoming results could materially change their investment cases.
Lovisa’s rapid international expansion and unusual mix of high margins and fast inventory turnover make its next update a test of execution and reporting risk.
Cochlear, CSL, ResMed and Sonic Healthcare each face a different healthcare question: pricing power, operational recovery, competition, demand or leadership.
Mineral Resources becomes a test of cash flow and capital allocation, with lithium, iron ore, Onslow and mining services shaping the valuation debate.
REA Group raises the question of whether AI agents threaten property platforms, while FDC Consolidated offers an unusually AI-light business to watch.
The episode’s central takeaway is that results matter most when they confirm—or undermine—the specific assumptions holding an investment case together.
What was said on this episode
34 statements · 21 positive · 9 negative · 1 mixed · 3 neutral
Lovisa combines high margins with fast inventory turnover.
“Lovisa combines them both.”
Listen at 2:43
Lovisa could eventually operate roughly three times its current store count.
“They're 1,100 stores, and I still think they're probably a third of where they could eventually be.”
Listen at 3:20
Lovisa’s JUULs concept will either become profitable or be shut down.
“Either the concept will make money, in which case it'll be a net positive for Lovisa's finances, or it won't make money, in which case they'll shut it down”
Listen at 5:29
Brett Blundy’s Lovisa share purchase should increase shareholder confidence.
“it should provide shareholders with a lot of confidence about where this company's going.”
Listen at 6:10
Cochlear’s price increases shifted demand toward competitors.
“demand kind of shifted over to them over the past 6 months or a year or so.”
Listen at 7:54
Damaged pricing power could undermine Cochlear’s investment case.
“if that is damaged, then it can be Yeah, that, that, that could really ruin its kind of buy case”
Listen at 9:29
Skin Candy has attractive store-level economics.
“the store-level economics are really attractive.”
Listen at 11:27
Skin Candy should be able to at least double its Australian store network.
“a significant rollout, which should be able to easily double the size of the Australian network.”
Listen at 11:51
Skin Candy’s valuation was expensive.
“The valuation was really expensive”
Listen at 13:19
Successful Horizon 2 yield improvements would give CSL a major competitive advantage.
“if they do, then that's a massive leg up over their competitors.”
Listen at 16:28
Horizon 2 could add approximately $500 million in CSL revenue.
“At current kind of sales prices, it'd add probably half a billion of revenue to the company.”
Listen at 16:33
Mineral Resources’ balance-sheet normalization is nearly guaranteed.
“I think that process is now almost guaranteed because you're going to have great cash flow from the 2 commodity businesses and you're going to have the asset sale details finalized.”
Listen at 21:34
Mineral Resources will likely pay substantial dividends for several years.
“my feeling is that they will go and pay some very hefty dividends for the next few years”
Listen at 21:54
Mineral Resources is unlikely to need capital or face financial distress.
“I don't think there's, there's certainly no future I can see where these guys are required to raise capital or go into, um, uh, into lockdown, um, or have any sort of financial problems.”
Listen at 22:17
Mineral Resources shares are undervalued in the $50s.
“The price now is too cheap. In the $50s is not the right price for Minres.”
Listen at 22:43
Philips will probably re-enter the CPAP market within about a year.
“Philips is probably going to be reentering in the next year or so.”
Listen at 24:49
Philips will probably price CPAP products cheaply to rebuild its reputation.
“Philips, which will probably come in and have to start selling cheaply to rebuild its reputation.”
Listen at 25:06
Management says GLP-1 users are more likely to continue CPAP therapy.
“management say that people taking those pills are actually more likely to continue therapy with CPAP devices.”
Listen at 26:39
Most users discontinue current GLP-1 drugs within six months.
“most people are off them within 6 months.”
Listen at 27:21
Current GLP-1 drugs probably will not be transformative long term.
“the current set of GLP-1s are probably not going to be the end. They're not going to be the ones that change the world.”
Listen at 27:27
Future oral GLP-1 drugs will probably be more effective or sustainable.
“the next ones, the pills, will probably be better again”
Listen at 27:40
Upcoming results will clarify how cyclical REA’s revenue is.
“We're about to find the answer to this puzzling question about REA behavior. How cyclical is REA?”
Listen at 29:50
REA Group’s growth comes entirely from price increases.
“all its growth comes from price rises.”
Listen at 31:23
Agentic AI could eliminate REA’s premium-listing revenue growth.
“All of it is coming from there. All that stuff will disappear if agentic AI starts to take over search.”
Listen at 31:55
AI agents are unlikely to pose a massive threat to REA Group.
“I'm not fully convinced about the AI agents being a massive threat to it”
Listen at 33:01
Sonic Healthcare should benefit substantially from AI.
“Sonic should be a huge AI beneficiary because it's all about diagnosis and analysis.”
Listen at 36:33
Sonic Healthcare will benefit overall even if GP visits stagnate or decline.
“I think it's going to be a net beneficiary even if GP visits stagnate or do decline.”
Listen at 36:53
Sonic Healthcare is currently very cheap and high quality.
“that's looking like a very interesting stock as well at the moment. It's silly, silly cheap, very good quality.”
Listen at 38:16
Sonic Healthcare offers a 5% yield at 18 times earnings.
“we got, yeah, a 5% yield, 18 times earning”
Listen at 38:38
Government changes could materially affect Sonic Healthcare’s Medicare pricing.
“Sonic's major issue is, uh, Medicare pricing, and that can change with a new government.”
Listen at 38:49
Sonic Healthcare is unlikely to deliver outsized returns.
“they're the kind of company you can't ever expect outsized returns from it”
Listen at 39:24
Sonic Healthcare should maintain small profits and decent returns on capital.
“it's also just going to keep having a small profit and be able to get a decent return on capital.”
Listen at 39:28
FDC Consolidated offers investors a business with little connection to AI.
“if you are like me and you're just sick of AI and AI saturation and you want a stock that has nothing to do with AI, FDC Consolidated, it looks kind of interesting.”
Listen at 39:52
FDC Consolidated has operated without external capital.
“A long history with zero external capital used.”
Listen at 40:11
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Intelligent InvestorListen to the full episode and explore every guest, topic, and moment on PodLume.